Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EPS (Weighted Average and Diluted) (2016 - 2025)

Ani Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 15 years, with the latest figure at $1.14 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 307.27% year-over-year to $1.14; the TTM value through Dec 2025 reached $3.32, up 391.23%, while the annual FY2025 figure was $3.32, 419.23% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $1.14 at Ani Pharmaceuticals, up from $1.13 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.14 in Q4 2025 and bottomed at -$1.87 in Q4 2021.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.06 (2021), against an average of -$0.17.
  • The largest annual shift saw EPS (Weighted Average and Diluted) crashed 12800.0% in 2022 before it surged 1266.67% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.87 in 2021, then skyrocketed by 84.49% to -$0.29 in 2022, then soared by 117.24% to $0.05 in 2023, then tumbled by 1200.0% to -$0.55 in 2024, then soared by 307.27% to $1.14 in 2025.
  • Per Business Quant, the three most recent readings for ANIP's EPS (Weighted Average and Diluted) are $1.14 (Q4 2025), $1.13 (Q3 2025), and $0.36 (Q2 2025).